NEW YORK, NY / ACCESSWIRE / January 20, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Splunk Inc. (NASDAQ:SPLK)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/splunk-inc-loss-submission-form?prid=12306&wire=1
Lead Plaintiff Deadline: February 2, 2021
Class Period: October 21, 2020 - December 2, 2020
Allegations against SPLK include that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Northern Dynasty Minerals Ltd. (NYSE:NAK)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/northern-dynasty-minerals-ltd-loss-submission-form?prid=12306&wire=1
Lead Plaintiff Deadline: February 2, 2021
Class Period: December 21, 2017 - November 25, 2020
Allegations against NAK include that: (1) the Company's Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (2) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (3) as a result, the Company's permit applications for the Pebble Project would be denied by the U.S. Army Corps of Engineers; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Minerva Neurosciences, Inc. (NASDAQ:NERV)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12306&wire=1
Lead Plaintiff Deadline: February 8, 2021
Class Period: May 15, 2017 - November 30, 2020
Allegations against NERV include that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong